tiprankstipranks
Trending News
More News >
Pennant Group Inc (PNTG)
NASDAQ:PNTG

Pennant Group (PNTG) AI Stock Analysis

Compare
97 Followers

Top Page

PNTG

Pennant Group

(NASDAQ:PNTG)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
$33.00
▲(12.28% Upside)
Pennant Group's strong earnings performance and technical momentum are the primary drivers of its score. While the financial performance is positive, the high valuation and leverage are concerns. The positive sentiment from the earnings call and successful acquisitions further bolster the score.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for services and effective business strategies, enhancing long-term market positioning.
Strategic Acquisition
The acquisition expands market reach and operational capabilities, providing a significant growth opportunity in new geographic areas.
Cash Flow Improvement
Improved cash flow enhances financial flexibility, supporting growth initiatives and providing a buffer against economic uncertainties.
Negative Factors
High Debt Levels
High leverage can strain financial resources and limit strategic options, posing risks to long-term financial stability.
Regulatory Challenges
Regulatory changes may reduce reimbursement rates, impacting revenue and profitability in the home health segment.
Integration Challenges
Integration issues can disrupt operations and delay realization of acquisition benefits, affecting short to medium-term performance.

Pennant Group (PNTG) vs. SPDR S&P 500 ETF (SPY)

Pennant Group Business Overview & Revenue Model

Company DescriptionThe Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.
How the Company Makes MoneyPennant Group generates revenue through multiple streams, primarily from its home health and hospice services as well as its senior living facilities. The company earns money by billing for medical services provided to patients, including skilled nursing, physical therapy, and other rehabilitative services. Revenue is supplemented through government programs such as Medicare and Medicaid, which reimburse providers for eligible healthcare services. Additionally, the company may have partnerships with hospitals and healthcare systems that refer patients to its facilities, thereby creating a steady flow of clients. Furthermore, the company focuses on operational efficiencies and improving patient outcomes, which can lead to higher reimbursement rates and increased revenue.

Pennant Group Earnings Call Summary

Earnings Call Date:Nov 05, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Mar 04, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment due to record revenue, successful acquisitions, and growth across key segments. While there are challenges related to integration and regulatory uncertainty, the company is confident in its ability to manage these effectively.
Q3-2025 Updates
Positive Updates
Record Revenue and Growth
In Q3, Pennant Group reported revenues of $229 million, an increase of $48.4 million or 26.8% compared to the previous year. Adjusted EBITDA increased by $2.2 million or 14.5%, and adjusted EPS rose by $0.04 or 15.4%.
Successful Acquisition of UnitedHealth Amedisys
Closed on the UnitedHealth Amedisys transaction, adding operations in the Southeast which are expected to deliver long-term growth potential.
Strong Performance in Home Health and Hospice Segment
Segment revenue increased by $37.9 million or 27.9%, while segment adjusted EBITDA rose by $5 million or 22.7% year-over-year.
Senior Living Segment Growth
Revenue in the Senior Living segment grew by 23.2% over the prior year quarter, with same-store occupancy reaching a new high of 81.8%.
Increased Annual Guidance
Raised full year revenue guidance to $911.4 million to $948.6 million and adjusted EPS to $1.14 to $1.18, a 23.4% increase over 2024 EPS.
Negative Updates
Potential Impact of 2026 Home Health Rule
The uncertainty surrounding the 2026 home health rule could impact operations, though less than 20% of revenue is from Medicare home health fee-for-service reimbursement.
Integration Challenges
Complex integration matters from the UnitedHealth Amedisys acquisition expected to create variability in results through the transition period.
Increased G&A Expenses
G&A expenses expected to remain slightly elevated during the transition period of recent acquisitions.
Company Guidance
In the third quarter of 2025, The Pennant Group reported strong financial performance with revenue reaching $229 million, a 26.8% increase compared to the previous year. Adjusted EBITDA was $17.3 million, marking a 14.5% rise, and adjusted EPS increased by 15.4% to $0.30. The company successfully closed the UnitedHealth Amedisys transaction on October 1, acquiring operations with trailing revenues of $189.3 million. Pennant raised its full-year guidance, anticipating revenue between $911.4 million and $948.6 million, adjusted EBITDA of $70.9 million to $73.8 million, and adjusted EPS of $1.14 to $1.18, reflecting a 23.4% EPS growth over 2024. Key operational highlights included a 27.9% increase in Home Health and Hospice segment revenue to $173.6 million, and a 23.2% rise in Senior Living segment revenue to $55.5 million. The company also reported improvements in clinical metrics, with a 4.1-star average CMS rating and a decrease in potentially preventable hospitalizations to 8.4%.

Pennant Group Financial Statement Overview

Summary
Pennant Group shows consistent revenue and profit growth, with improvements in cash flow and profitability metrics. However, high leverage remains a concern, though it is improving.
Income Statement
75
Positive
Pennant Group has demonstrated consistent revenue growth, with a notable 6.05% increase in TTM. Gross profit margin has slightly improved to 13.54%, indicating stable cost management. Net profit margin is modest at 3.36%, but shows improvement over previous years. EBIT and EBITDA margins are stable, reflecting efficient operations. Overall, the income statement reflects positive growth trends and improving profitability.
Balance Sheet
65
Positive
The balance sheet shows a high debt-to-equity ratio of 1.00 in TTM, indicating significant leverage, though it has improved from previous years. Return on equity is reasonable at 9.94%, suggesting effective use of equity. The equity ratio is moderate, reflecting a balanced asset structure. While leverage remains a concern, the company is showing signs of improving financial stability.
Cash Flow
70
Positive
Operating cash flow has increased, with a TTM coverage ratio of 0.40, indicating better cash generation relative to net income. Free cash flow growth is strong at 11.35%, and the free cash flow to net income ratio is healthy at 0.78. This suggests that the company is effectively converting its earnings into cash, supporting its financial flexibility and growth initiatives.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue847.27M695.24M544.89M473.24M439.69M390.95M
Gross Profit130.85M93.76M67.04M58.59M48.59M54.89M
EBITDA52.04M44.44M30.64M17.61M9.46M23.82M
Net Income26.70M22.56M13.38M6.64M2.70M15.74M
Balance Sheet
Total Assets753.64M679.52M539.69M512.12M530.30M506.98M
Cash, Cash Equivalents and Short-Term Investments2.34M24.25M6.06M2.08M5.19M43.00K
Total Debt302.81M273.09M329.63M326.57M355.24M319.00M
Total Liabilities410.60M367.56M394.18M386.46M416.05M405.80M
Stockholders Equity321.91M293.28M140.34M121.01M110.20M96.58M
Cash Flow
Free Cash Flow36.10M30.31M24.98M-5.13M-24.53M42.95M
Operating Cash Flow47.91M39.30M33.09M9.04M-18.22M50.20M
Investing Cash Flow-79.35M-70.68M-30.22M-24.24M-20.12M-41.62M
Financing Cash Flow29.31M49.57M1.11M12.08M43.49M-8.95M

Pennant Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price29.39
Price Trends
50DMA
26.17
Positive
100DMA
25.36
Positive
200DMA
25.79
Positive
Market Momentum
MACD
1.07
Negative
RSI
71.08
Negative
STOCH
68.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PNTG, the sentiment is Positive. The current price of 29.39 is above the 20-day moving average (MA) of 28.29, above the 50-day MA of 26.17, and above the 200-day MA of 25.79, indicating a bullish trend. The MACD of 1.07 indicates Negative momentum. The RSI at 71.08 is Negative, neither overbought nor oversold. The STOCH value of 68.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PNTG.

Pennant Group Risk Analysis

Pennant Group disclosed 42 risk factors in its most recent earnings report. Pennant Group reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pennant Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$1.03B38.8510.87%29.89%10.33%
72
Outperform
$1.34B35.428.07%6.26%-19.33%
70
Outperform
$1.89B17.535.57%1.64%-22.96%-59.35%
63
Neutral
$1.19B33.027.30%2.29%17.50%154.28%
56
Neutral
$1.12B119.161.29%68.17%-85.42%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
$607.71M-2.26-35.90%-11.42%-617.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PNTG
Pennant Group
29.39
1.24
4.40%
AMN
AMN Healthcare Services
16.25
-7.27
-30.91%
HCSG
Healthcare Services
19.14
7.54
65.00%
SEM
Select Medical
15.01
-2.95
-16.43%
USPH
US Physical Therapy
78.72
-12.13
-13.35%
ASTH
Astrana Health
22.64
-12.40
-35.39%

Pennant Group Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Pennant Group Expands Credit Facility by $100 Million
Positive
Nov 5, 2025

On November 3, 2025, The Pennant Group, Inc. expanded its credit facility by $100 million, bringing the total to $350 million, through a First Amendment with Truist Bank and other lenders. This expansion, which retains the same interest rate and maturity date as the existing facility, aims to refinance part of the outstanding revolving loans and support future growth initiatives, enhancing the company’s financial flexibility and strategic opportunities.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Pennant Group Reports Q3 2025 Revenue Surge
Positive
Nov 5, 2025

On November 5, 2025, The Pennant Group announced its third-quarter 2025 financial results, highlighting a 26.8% increase in total revenue to $229 million compared to the previous year. The company reported a GAAP diluted earnings per share of $0.17 and an adjusted earnings per share of $0.30. Notably, the company completed a significant acquisition of 54 operations from UnitedHealth Group and Amedisys on October 1, 2025, marking its largest transaction to date. This expansion into the Southeast is expected to enhance Pennant’s market presence and operational capabilities.

M&A TransactionsBusiness Operations and Strategy
Pennant Group Expands with Strategic Acquisition in Southeast
Positive
Oct 2, 2025

On October 1, 2025, The Pennant Group, Inc. completed the acquisition of certain home health, hospice, and personal care operations from UnitedHealth Group and Amedisys, Inc. for $146.5 million. This strategic acquisition, part of an antitrust settlement, expands Pennant’s presence into Tennessee, Georgia, and Alabama, marking a significant growth opportunity in the Southeast U.S. The transition is supported by a services agreement with UnitedHealth, and Pennant aims to leverage its operational excellence to integrate these new locations into its portfolio.

M&A TransactionsBusiness Operations and Strategy
Pennant Group Amends Purchase Agreement with UnitedHealth
Positive
Oct 2, 2025

On October 1, 2025, The Pennant Group, Inc. and its subsidiaries amended a purchase agreement with UnitedHealth Group and Amedisys to acquire additional equity interests and assets related to home health, hospice, and palliative care services. The amendment increased the purchase price from $102,484,000 to $146,531,160 to reflect the acquisition of additional assets and entities, impacting the company’s operational scope and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025